| Accession | PRJCA016175 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Title | IHC Biomarker data of a Phase I/II Study of TJ004309 Combination with Toripalimab for Advanced Solid Tumor | ||||||||
| Relevance | Medical | ||||||||
| Data types | Biomarker | ||||||||
| Organisms | Homo sapiens | ||||||||
| Description | TJ004309STM102, A Phase I/II Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Efficacy of TJ004309(Anti-CD73 Antibody) in Combination with Toripalimab in Patients with Advanced or Metastatic Solid Tumor,CD73 is a rate-limiting enzyme in adenosine pathway promoting immune suppression in tumor microenvironment | ||||||||
| Sample scope | Biomarker | ||||||||
| Release date | 2023-06-03 | ||||||||
| Grants |
|
||||||||
| Submitter | Mei Huang (mei.huang@i-mabbiopharma.com) | ||||||||
| Organization | I-Mab Biopharma Co.,Ltd | ||||||||
| Submission date | 2023-04-11 |
| Resource name | Description |
|---|